May 18, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 12, 2026 07:00AM
Feb 12, 2026 07:00AM
Dec 17, 2025 07:02AM
Dec 17, 2025 07:00AM
Nov 10, 2025 07:00AM Compugen Reports Third Quarter 2025 Results
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 13, 2025 07:00AM
Oct 13, 2025 07:00AM
Aug 6, 2025 07:00AM
Jul 21, 2025 07:00AM
Jun 9, 2025 08:00AM DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
Jun 1, 2025 09:00AM
May 19, 2025 07:00AM
May 13, 2025 07:04AM
May 13, 2025 07:00AM
Mar 4, 2025 07:00AM
Feb 26, 2025 07:00AM
Jan 30, 2025 11:00PM TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
Jan 8, 2025 07:00AM
Nov 27, 2024 07:03AM
Nov 27, 2024 07:00AM
Nov 12, 2024 07:00AM
Nov 11, 2024 07:00AM
Nov 5, 2024 09:00AM
Oct 29, 2024 07:00AM Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Oct 7, 2024 07:00AM
Sep 9, 2024 07:00AM
Aug 29, 2024 07:00AM
Aug 6, 2024 07:00AM
Jul 29, 2024 07:00AM
Mar 5, 2024 07:00AM
Dec 19, 2023 07:01AM Gilead Sciences (GILD) and Compugen (CGEN) Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Dec 19, 2023 07:00AM
Nov 6, 2023 07:05AM
Nov 6, 2023 07:00AM
Feb 27, 2023 07:00AM
Feb 14, 2023 07:00AM
Dec 6, 2022 07:00AM
Dec 1, 2022 07:09AM Compugen's (CGEN) COM701 in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients
Dec 1, 2022 07:00AM
Nov 7, 2022 08:05AM
Nov 7, 2022 08:04AM
Nov 7, 2022 08:00AM
Nov 7, 2022 08:00AM
May 11, 2022 06:45AM
Feb 24, 2022 07:19AM Compugen (CGEN) Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
Feb 24, 2022 07:05AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All